DUBLIN, August 04, 2021--(BUSINESS WIRE)--The "Pharmaceutical Gelatin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)" report has been added to ResearchAndMarkets.com's offering.
The Pharmaceutical Gelatin market studied is expected to grow with an estimated CAGR of 5.5%, over the forecast period.
COVID 19 has a great impact on gelatin production and the supply chain. Lonza, a key player in the capsules segment has reported that COVID 19 has impacted the demand and supply chain of pharmaceutical capsules, on the other side there is an increased demand for Over counter (OTC) medication too, hence they expect the market to be flat in 2021. COVID 19 is also having a positive tail as this pandemic has raised demand in capsules and tablet manufacturing as there is high consumption.
Types of gelatin are A gelatin - Gelatin produced from the acidic treatment of porcine skin. B gelatin - Gelatin produced from the alkaline treatment of bovine skin. An article published on Biotechnological Processing of Laying Hen Paw Collagen into Gelatins at Multidisciplinary Digital Publishing Institute in Nov 2020 states that hen paws are the alternative source for gelatin which contains a high proportion of collagen (apprx.77%), is an excellent source of raw materials for preparing gelatins.
Gelatin's remarkable functional properties, its ability to stabilize, thicken, gel, foam or bind, It's high usage in surgeries as hemostat reagent, coating of hard & soft-gel capsules, which facilitates ease in swallowing and provides protection from environmental changes there by increasing the shell-life of the product, made it predominant in pharmaceutical industry.
Lonza, to increase the overall production capacity of capsules within CHI's Capsugel portfolio by 30 billion capsules annually, announced a USD 93 million investment in its Capsules and Health Ingredients (CHI) Division in Oct 2020 which is a dosage form delivery partner to the health nutrition and biopharma industry.
The advancements in technology and rise in incidence of diseases are driving the factors for pharmaceutical gelatin. For instance vaccine, to ensure the safety and effectiveness of the vaccine during storage and transport, gelatin derived from pork is being used as stabilizer, which is a driving factor for high demand of pharmaceutical grade gelatin in the present market.
Especially in countries like the United States, Canada where there is high prevalence of chronic diseases. Hence, owing to above mentioned factors, the market is expected to witness significant growth in the future.
The major players covered in the pharmaceutical gelatin market are Darling Ingredients INC, Nitta Gelatin INC, Gelita AG, Tessenderlo Group, Weishardt.
Key Topics Covered:
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Cancer Worldwide
4.2.2 Technological Advancements in Diagnostic Testing
4.2.3 Increasing Demand for Point-Of-Care Treatment
4.3 Market Restraints
4.3.1 High Cost of Molecular Diagnostic Tests
4.3.2 Lack of Skilled Workforce and Stringent Regulatory Framework
4.4 Porter's Five Force Analysis
5 MARKET SEGMENTATION
5.1 Product Type
5.1.3 Other Product types
5.2 Technology Type
5.2.1 Polymerase Chain Reaction (PCR)
5.2.2 Isothermal Nucleic Acid Amplification Technology (INAAT)
5.2.3 DNA Sequencing and Next-Generation Sequencing
5.2.4 In-situ Hybridization
5.2.5 Mass Spectrometry
5.2.6 Transcription Mediated Amplification (TMA)
5.2.7 Chips and Microarrays
5.2.8 Other Technology Types
5.3 Application Type
5.3.1 Breast Cancer
5.3.2 Prostate Cancer
5.3.3 Colorectal Cancer
5.3.4 Lung Cancer
5.3.5 Blood Cancer
5.3.6 Liver Cancer
5.3.7 Cervical Cancer
5.3.8 Other Application Types
5.4.2 Diagnostic Centers
5.4.3 Other End-users
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 F-Hoffmann La-Roche Ltd
6.1.3 Bayer AG
6.1.4 Becton, Dickinson and Company
6.1.5 Danaher Corporation (Cepheid)
6.1.7 Siemens Healthineers
6.1.8 Sysmex Corporation (Sysmex Europe GmbH)
6.1.9 Illumina, Inc.
6.1.10 Thermo Fisher Scientific Inc.
6.1.11 bioMerieux SA
6.1.12 Veracyte, Inc
6.1.13 Agilient Technologies, Inc. (Dako)
6.1.14 TBG Diagnostics Limited
6.1.15 HTG Molecular Diagnostics, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
For more information about this report visit https://www.researchandmarkets.com/r/apjj9e
View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005546/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900